Dendritic cells and anergic type I NKT cells play a crucial role in sulfatide-mediated immune regulation in experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 193, Issue 3, 2014, Pages 1035-1046

  Maricic, Igor ^a   Halder, Ramesh ^a   Bischof, Felix ^b   Kumar, Vipin ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD4 ANTIGEN; CIS TETRACOSENOYL SULFATIDE; MYELIN PROTEOLIPID PROTEIN[139-151]; PROTEOLIPID PROTEIN; SULFATIDE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; DENDRITIC CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MICROGLIA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TYPE I NATURAL KILLER T CELL; TYPE II NATURAL KILLER T CELL;

ADOPTIVE TRANSFER; ANIMALS; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; CLONAL ANERGY; DENDRITIC CELLS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN PROTEOLIPID PROTEIN; NATURAL KILLER T-CELLS; SULFOGLYCOSPHINGOLIPIDS;

EID: 84906084966     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302898     Document Type: Article

References (58)

1. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
2. Brigl, M., and M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890.
3. Arrenberg, P., R. Halder, and V. Kumar. 2009. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J. Cell. Physiol. 218: 246-250.
4. Kronenberg, M., and A. Rudensky. 2005. Regulation of immunity by selfreactive T cells. Nature 435: 598-604.
5. Kumar, V. 2013. NKT-cell subsets: promoters and protectors in inflammatory liver disease. J. Hepatol. 59: 618-620.
6. Rhost, S., S. Sedimbi, N. Kadri, and S. L. Cardell. 2012. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand. J. Immunol. 76: 246-255.
7. Terabe, M., and J. A. Berzofsky. 2007. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28: 491-496.
8. Godfrey, D. I., S. Stankovic, and A. G. Baxter. 2010. Raising the NKT cell family. Nat. Immunol. 11: 197-206.
9. Girardi, E., I.Maricic, J.Wang, T. T.Mac, P. Iyer, V. Kumar, and D. M. Zajonc. 2012. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat. Immunol. 13: 851-856.
10. Jahng, A., I. Maricic, C. Aguilera, S. Cardell, R. C. Halder, and V. Kumar. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199: 947-957.
11. Rhost, S., L. Löfbom, B. M. Rynmark, B. Pei, J. E. Mansson, S. Teneberg, M. Blomqvist, and S. L. Cardell. 2012. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur. J. Immunol. 42: 2851-2860.
12. Shamshiev, A., A. Donda, I. Carena, L. Mori, L. Kappos, and G. De Libero. 1999. Self glycolipids as T-cell autoantigens. Eur. J. Immunol. 29: 1667-1675.
13. Zajonc, D. M., I. Maricic, D. Wu, R. Halder, K. Roy, C. H. Wong, V. Kumar, and I. A. Wilson. 2005. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202: 1517-1526.
14. Lubetzki, C., Y. Thuillier, A. Galli, O. Lyon-Caen, F. Lhermitte, and B. Zalc. 1989. Galactosylceramide: a reliable serum index of demyelination in multiple sclerosis. Ann. Neurol. 26: 407-409.
15. Sela, B. A., G. Konat, and H. Offner. 1982. Elevated ganglioside concentration in serum and peripheral blood lymphocytes from multiple sclerosis patients in remission. J. Neurol. Sci. 54: 143-148.
16. Endo, T., D. D. Scott, S. S. Stewart, S. K. Kundu, and D. M. Marcus. 1984. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. Adv. Exp. Med. Biol. 174: 455-461.
17. Ilyas, A. A., Z. W. Chen, and S. D. Cook. 2003. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 139: 76-80.
18. Shamshiev, A., A. Donda, T. I. Prigozy, L. Mori, V. Chigorno, C. A. Benedict, L. Kappos, S. Sonnino, M. Kronenberg, and G. De Libero. 2000. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 13: 255-264.
19. Battistini, L., F. R. Fischer, C. S. Raine, and C. F. Brosnan. 1996. CD1b is expressed in multiple sclerosis lesions. J. Neuroimmunol. 67: 145-151.
20. Jäger, A., and V. K. Kuchroo. 2010. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand. J. Immunol. 72: 173-184.
21. Kumar, V., and E. Sercarz. 1999. Distinct levels of regulation in organ-specific autoimmune diseases. Life Sci. 65: 1523-1530.
22. O'Garra, A., L. Steinman, and K. Gijbels. 1997. CD4+ T-cell subsets in autoimmunity. Curr. Opin. Immunol. 9: 872-883.
23. Jahng, A. W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, and V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1789-1799.
24. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
25. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagómez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811.
26. Yamamura, T., K. Miyamoto, Z. Illés, E. Pál, M. Araki, and S. Miyake. 2004. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr. Top. Med. Chem. 4: 561-567.
27. Kanter, J. L., S. Narayana, P. P. Ho, I. Catz, K. G. Warren, R. A. Sobel, L. Steinman, and W. H. Robinson. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12: 138-143.
28. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCRmediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629.
29. Halder, R. C., C. Aguilera, I. Maricic, and V. Kumar. 2007. Type II NKT cellmediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Invest. 117: 2302-2312.
30. Bischof, F., M. Hofmann, T. N. Schumacher, F. A. Vyth-Dreese, R. Weissert, H. Schild, A. M. Kruisbeek, and A. Melms. 2004. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J. Immunol. 172: 2878-2884.
31. Crawford, F., H. Kozono, J. White, P. Marrack, and J. Kappler. 1998. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8: 675-682.
32. Kozono, H., J. White, J. Clements, P. Marrack, and J. Kappler. 1994. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 369: 151-154.
33. Schatz, P. J. 1993. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology (N. Y.) 11: 1138-1143.
34. Arrenberg, P., I. Maricic, and V. Kumar. 2011. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 140: 646-655.
35. Yoshimoto, T., A. Bendelac, J. Hu-Li, and W. E. Paul. 1995. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc. Natl. Acad. Sci. USA 92: 11931-11934.
36. Subramanian, L., H. Blumenfeld, R. Tohn, D. Ly, C. Aguilera, I. Maricic, J. E. Mansson, K. Buschard, V. Kumar, and T. L. Delovitch. 2012. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected]. [Published erratum appears in 2012 PLoS One.7(6), doi:10.1371/annotation/b5c4c567-f17b- 4ebba6ea-d3cdff36d5ce and 2012 PLoS One. 2012;7(7), doi:10.1371/annotation/ b737472b-f38a-4ef6-b10c-e052c3b66148.] PLoS ONE 7: e37771.
37. Arrenberg, P., R. Halder, Y. Dai, I. Maricic, and V. Kumar. 2010. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc. Natl. Acad. Sci. USA 107: 10984-10989.
38. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino. 2003. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33: 1830-1838.
39. Mars, L. T., L. Araujo, P. Kerschen, S. Diem, E. Bourgeois, L. P. Van, N. Carrié, M. Dy, R. S. Liblau, and A. Herbelin. 2009. Invariant NKT cells inhibit development of the Th17 lineage. Proc. Natl. Acad. Sci. USA 106: 6238-6243.
40. Yang, S. H., J. P. Lee, H. R. Jang, R. H. Cha, S. S. Han, U. S. Jeon, D. K. Kim, J. Song, D. S. Lee, and Y. S. Kim. 2011. Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury. J. Am. Soc. Nephrol. 22: 1305-1314.
41. Zhang, G., H. Nie, J. Yang, X. Ding, Y. Huang, H. Yu, R. Li, Z. Yuan, and S. Hu. 2011. Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 301: L975-L984.
42. Halder, R. C., A. Jahng, I. Maricic, and V. Kumar. 2007. Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem. Res. 32: 257-262.
43. Ambrosino, E., M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky. 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179: 5126-5136.
44. Gillessen, S., Y. N. Naumov, E. E. Nieuwenhuis, M. A. Exley, F. S. Lee, N. Mach, A. D. Luster, R. S. Blumberg, M. Taniguchi, S. P. Balk, et al. 2003. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. USA 100: 8874-8879.
45. Wang, J., S. Cho, A. Ueno, L. Cheng, B. Y. Xu, M. D. Desrosiers, Y. Shi, and Y. Yang. 2008. Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation. [Published erratum appears in 2008 J. Immunol. 181: 5803.] J. Immunol. 181: 2438-2445.
46. Parekh, V. V., L. Wu, D. Olivares-Villagómez, K. T. Wilson, and L. Van Kaer. 2013. Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J. Immunol. 190: 1948-1960.
47. Denney, L., W. L. Kok, S. L. Cole, S. Sanderson, A. J. McMichael, and L. P. Ho. 2012. Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome. J. Immunol. 189: 551-557.
48. Chen, Y. G., C. M. Choisy-Rossi, T. M. Holl, H. D. Chapman, G. S. Besra, S. A. Porcelli, D. J. Shaffer, D. Roopenian, S. B. Wilson, and D. V. Serreze. 2005. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J. Immunol. 174: 1196-1204.
49. Kojo, S., K. Seino, M. Harada, H. Watarai, H. Wakao, T. Uchida, T. Nakayama, and M. Taniguchi. 2005. Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J. Immunol. 175: 3648-3655.
50. Venken, K., T. Decruy, S. Aspeslagh, S. Van Calenbergh, B. N. Lambrecht, and D. Elewaut. 2013. Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells. J. Immunol. 191: 2174-2183.
51. Kadri, N., E. Korpos, S. Gupta, C. Briet, L. Löfbom, H. Yagita, A. Lehuen, C. Boitard, D. Holmberg, L. Sorokin, and S. L. Cardell. 2012. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J. Immunol. 188: 3138-3149.
52. Brandl, C., S. Ortler, T. Herrmann, S. Cardell, M. B. Lutz, and H. Wiendl. 2010. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells. PLoS ONE 5: e10800.
53. Jack, C., F. Ruffini, A. Bar-Or, and J. P. Antel. 2005. Microglia and multiple sclerosis. J. Neurosci. Res. 81: 363-373.
54. Chastain, E. M., D. S. Duncan, J. M. Rodgers, and S. D. Miller. 2011. The role of antigen presenting cells in multiple sclerosis. Biochim. Biophys. Acta 1812: 265-274.
55. Lassmann, H., and J. van Horssen. 2011. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 585: 3715-3723.
56. Jeon, S. B., H. J. Yoon, S. H. Park, I. H. Kim, and E. J. Park. 2008. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. J. Immunol. 181: 8077-8087.
57. Kwiecinski, J., S. Rhost, L. Löfbom, M. Blomqvist, J. E. Mansson, S. L. Cardell, and T. Jin. 2013. Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway. Infect. Immun. 81: 1114-1120.
58. Izhak, L., E. Ambrosino, S. Kato, S. T. Parish, J. J. O'Konek, H. Weber, Z. Xia, D. Venzon, J. A. Berzofsky, and M. Terabe. 2013. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res. 73: 1514-1523.